HUE027263T2 - 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer - Google Patents

Info

Publication number

HUE027263T2

HUE027263T2 HUE10759940A HUE10759940A HUE027263T2 HU E027263 T2 HUE027263 T2 HU E027263T2 HU E10759940 A HUE10759940 A HU E10759940A HU E10759940 A HUE10759940 A HU E10759940A HU E027263 T2 HUE027263 T2 HU E027263T2

Authority

HU

Hungary

Prior art keywords

formula

methyl

oxo

thiadiazol

compound

Prior art date

2009-07-08

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims description 119
• 201000011510 cancer Diseases 0.000 title claims description 89
• 238000011282 treatment Methods 0.000 title claims description 69
• 150000001875 compounds Chemical class 0.000 claims description 309
• 125000005843 halogen group Chemical group 0.000 claims description 107
• 239000012453 solvate Substances 0.000 claims description 100
• 150000003839 salts Chemical class 0.000 claims description 93
• 125000003118 aryl group Chemical group 0.000 claims description 88
• -1 CrG Chemical group 0.000 claims description 82
• 239000000203 mixture Substances 0.000 claims description 49
• 238000000034 method Methods 0.000 claims description 45
• 239000003814 drug Substances 0.000 claims description 44
• 229910052717 sulfur Inorganic materials 0.000 claims description 42
• 125000001424 substituent group Chemical group 0.000 claims description 41
• 125000000217 alkyl group Chemical group 0.000 claims description 39
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 34
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
• 125000004429 atom Chemical group 0.000 claims description 31
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 27
• 229940124597 therapeutic agent Drugs 0.000 claims description 26
• 125000005842 heteroatom Chemical group 0.000 claims description 23
• 229910052757 nitrogen Inorganic materials 0.000 claims description 23
• 239000002671 adjuvant Substances 0.000 claims description 21
• 230000000694 effects Effects 0.000 claims description 20
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 19
• 229910052799 carbon Inorganic materials 0.000 claims description 16
• 239000013066 combination product Substances 0.000 claims description 16
• 229940127555 combination product Drugs 0.000 claims description 16
• 239000003085 diluting agent Substances 0.000 claims description 16
• 238000004519 manufacturing process Methods 0.000 claims description 15
• 239000012190 activator Substances 0.000 claims description 12
• 125000004432 carbon atom Chemical group C* 0.000 claims description 12
• 239000008194 pharmaceutical composition Substances 0.000 claims description 12
• 229910052739 hydrogen Inorganic materials 0.000 claims description 11
• 230000008569 process Effects 0.000 claims description 11
• 239000007787 solid Substances 0.000 claims description 11
• 206010012601 diabetes mellitus Diseases 0.000 claims description 8
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 8
• 239000002253 acid Substances 0.000 claims description 7
• 239000000556 agonist Substances 0.000 claims description 7
• 239000003112 inhibitor Substances 0.000 claims description 7
• 238000002360 preparation method Methods 0.000 claims description 7
• 229910052740 iodine Inorganic materials 0.000 claims description 6
• 230000001225 therapeutic effect Effects 0.000 claims description 6
• 239000000460 chlorine Substances 0.000 claims description 5
• 210000001072 colon Anatomy 0.000 claims description 5
• 229940123208 Biguanide Drugs 0.000 claims description 4
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
• 229910052801 chlorine Inorganic materials 0.000 claims description 4
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
• 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 4
• 208000032839 leukemia Diseases 0.000 claims description 4
• 210000002307 prostate Anatomy 0.000 claims description 4
• 239000000126 substance Substances 0.000 claims description 4
• 125000001544 thienyl group Chemical group 0.000 claims description 4
• VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 3
• 229940122815 Aromatase inhibitor Drugs 0.000 claims description 3
• 108010041191 Sirtuin 1 Proteins 0.000 claims description 3
• 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
• 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 3
• 239000003886 aromatase inhibitor Substances 0.000 claims description 3
• 239000000824 cytostatic agent Substances 0.000 claims description 3
• 230000001085 cytostatic effect Effects 0.000 claims description 3
• 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
• 239000000194 fatty acid Substances 0.000 claims description 3
• 229930195729 fatty acid Natural products 0.000 claims description 3
• 150000004665 fatty acids Chemical class 0.000 claims description 3
• 229910052736 halogen Inorganic materials 0.000 claims description 3
• 150000002367 halogens Chemical class 0.000 claims description 3
• 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 2
• 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 3
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 3
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
• UFGJFRRXTBBPQS-RGCXKDKSSA-N (3r)-5-[(1s,3s,4ar,8ar)-3-hydroxy-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]-3-methylpentanoic acid Chemical class CC1(C)CCC[C@@]2(C)[C@H](CC[C@@H](C)CC(O)=O)C(=C)[C@@H](O)C[C@@H]21 UFGJFRRXTBBPQS-RGCXKDKSSA-N 0.000 claims 1
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
• 208000031454 Childhood-onset autosomal recessive slowly progressive spinocerebellar ataxia Diseases 0.000 claims 1
• 101100456896 Drosophila melanogaster metl gene Proteins 0.000 claims 1
• 206010014561 Emphysema Diseases 0.000 claims 1
• 241000233866 Fungi Species 0.000 claims 1
• LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
• 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 1
• 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 1
• 229920000715 Mucilage Polymers 0.000 claims 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
• 102000000344 Sirtuin 1 Human genes 0.000 claims 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
• 239000000853 adhesive Substances 0.000 claims 1
• 238000011319 anticancer therapy Methods 0.000 claims 1
• 201000010150 autosomal recessive spinocerebellar ataxia 7 Diseases 0.000 claims 1
• 150000001721 carbon Chemical group 0.000 claims 1
• 239000002131 composite material Substances 0.000 claims 1
• 230000007812 deficiency Effects 0.000 claims 1
• 239000000551 dentifrice Substances 0.000 claims 1
• 125000003963 dichloro group Chemical group Cl* 0.000 claims 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
• NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims 1
• CJXGPJZUDUOZDX-UHFFFAOYSA-N fluoromethanone Chemical group F[C]=O CJXGPJZUDUOZDX-UHFFFAOYSA-N 0.000 claims 1
• 125000001207 fluorophenyl group Chemical group 0.000 claims 1
• 229960000304 folic acid Drugs 0.000 claims 1
• 235000019152 folic acid Nutrition 0.000 claims 1
• 239000011724 folic acid Substances 0.000 claims 1
• 235000012432 gingerbread Nutrition 0.000 claims 1
• 125000003147 glycosyl group Chemical group 0.000 claims 1
• 230000000004 hemodynamic effect Effects 0.000 claims 1
• 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 1
• 150000002466 imines Chemical class 0.000 claims 1
• 230000001459 mortal effect Effects 0.000 claims 1
• 238000006452 multicomponent reaction Methods 0.000 claims 1
• HWYHDWGGACRVEH-UHFFFAOYSA-N n-methyl-n-(4-pyrrolidin-1-ylbut-2-ynyl)acetamide Chemical compound CC(=O)N(C)CC#CCN1CCCC1 HWYHDWGGACRVEH-UHFFFAOYSA-N 0.000 claims 1
• 210000002824 peroxisome Anatomy 0.000 claims 1
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
• 102000005962 receptors Human genes 0.000 claims 1
• 108020003175 receptors Proteins 0.000 claims 1
• 210000003296 saliva Anatomy 0.000 claims 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
• XWMXMWHHTIEXRE-UHFFFAOYSA-N thiadiazole 1-oxide Chemical compound O=S1C=CN=N1 XWMXMWHHTIEXRE-UHFFFAOYSA-N 0.000 claims 1
• 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
• 210000004027 cell Anatomy 0.000 description 84
• 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 52
• 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 52
• 238000006243 chemical reaction Methods 0.000 description 45
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 44
• 125000001072 heteroaryl group Chemical group 0.000 description 36
• 238000004128 high performance liquid chromatography Methods 0.000 description 36
• 238000012360 testing method Methods 0.000 description 36
• 238000005160 1H NMR spectroscopy Methods 0.000 description 32
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
• 229910052760 oxygen Inorganic materials 0.000 description 24
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 23
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
• 239000000047 product Substances 0.000 description 23
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
• KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 22
• 238000003556 assay Methods 0.000 description 20
• 238000009472 formulation Methods 0.000 description 20
• 239000002904 solvent Substances 0.000 description 20
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
• 206010006187 Breast cancer Diseases 0.000 description 19
• 208000026310 Breast neoplasm Diseases 0.000 description 19
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
• 239000002585 base Substances 0.000 description 16
• 239000000243 solution Substances 0.000 description 16
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
• 201000008980 hyperinsulinism Diseases 0.000 description 14
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 13
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 13
• 235000019439 ethyl acetate Nutrition 0.000 description 13
• 230000003451 hyperinsulinaemic effect Effects 0.000 description 13
• 230000026731 phosphorylation Effects 0.000 description 13
• 238000006366 phosphorylation reaction Methods 0.000 description 13
• 241000699670 Mus sp. Species 0.000 description 12
• 201000010099 disease Diseases 0.000 description 12
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 11
• 208000035475 disorder Diseases 0.000 description 11
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
• 240000008042 Zea mays Species 0.000 description 10
• 230000004913 activation Effects 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
• 230000037361 pathway Effects 0.000 description 10
• 239000000651 prodrug Substances 0.000 description 10
• 229940002612 prodrug Drugs 0.000 description 10
• 125000004076 pyridyl group Chemical group 0.000 description 10
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
• 125000004433 nitrogen atom Chemical group N* 0.000 description 9
• 239000002953 phosphate buffered saline Substances 0.000 description 9
• 230000035755 proliferation Effects 0.000 description 9
• 125000000714 pyrimidinyl group Chemical group 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 9
• AZQPOQDQXYPOTD-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-thiadiazolidin-3-one Chemical compound FC(F)(F)C1=CC=CC(CN2C(SNC2=O)=NC=2C=C(Cl)C(Cl)=CC=2)=C1 AZQPOQDQXYPOTD-UHFFFAOYSA-N 0.000 description 8
• 229920001817 Agar Polymers 0.000 description 8
• 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 8
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 8
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
• 239000008272 agar Substances 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• WMOWRZATFPXDAS-UHFFFAOYSA-N n-[3-oxo-2-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-thiadiazol-5-yl]benzamide Chemical compound FC(F)(F)C1=CC=CC(CN2C(N=C(NC(=O)C=3C=CC=CC=3)S2)=O)=C1 WMOWRZATFPXDAS-UHFFFAOYSA-N 0.000 description 8
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
• CQPHWPNJPUDZJN-UHFFFAOYSA-N 5-(3,4-dichloroanilino)-2-(2-phenoxyethyl)-1,2,4-thiadiazol-3-one Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(S1)=NC(=O)N1CCOC1=CC=CC=C1 CQPHWPNJPUDZJN-UHFFFAOYSA-N 0.000 description 7
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 7
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
• 206010016654 Fibrosis Diseases 0.000 description 7
• 206010027476 Metastases Diseases 0.000 description 7
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 7
• 101710151472 Neuroendocrine convertase 1 Proteins 0.000 description 7
• 125000004122 cyclic group Chemical group 0.000 description 7
• 230000004761 fibrosis Effects 0.000 description 7
• 125000001153 fluoro group Chemical group F* 0.000 description 7
• 125000000524 functional group Chemical group 0.000 description 7
• 230000009401 metastasis Effects 0.000 description 7
• 238000010899 nucleation Methods 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• LKOHEZNWJKGELG-UHFFFAOYSA-N 2-(2-phenylethyl)-5-[4-(trifluoromethoxy)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(S1)=NC(=O)N1CCC1=CC=CC=C1 LKOHEZNWJKGELG-UHFFFAOYSA-N 0.000 description 6
• HGTKLMBPGLDIFR-UHFFFAOYSA-N 2-(2-phenylethyl)-5-[4-(trifluoromethyl)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(S1)=NC(=O)N1CCC1=CC=CC=C1 HGTKLMBPGLDIFR-UHFFFAOYSA-N 0.000 description 6
• HNGKUGUJMPSSGY-UHFFFAOYSA-N 2-[(3,4-difluorophenyl)methyl]-5-[4-(trifluoromethoxy)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)N=C(NC=2C=CC(OC(F)(F)F)=CC=2)S1 HNGKUGUJMPSSGY-UHFFFAOYSA-N 0.000 description 6
• XJTWKJIKTOVTGK-UHFFFAOYSA-N 2-[(3,4-difluorophenyl)methyl]-5-[4-(trifluoromethyl)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)N=C(NC=2C=CC(=CC=2)C(F)(F)F)S1 XJTWKJIKTOVTGK-UHFFFAOYSA-N 0.000 description 6
• RJZSSMHOEKAAPX-UHFFFAOYSA-N 2-[(3-fluorophenyl)methyl]-5-[4-(trifluoromethoxy)anilino]-1,2,4-thiadiazol-3-one Chemical compound FC1=CC=CC(CN2C(N=C(NC=3C=CC(OC(F)(F)F)=CC=3)S2)=O)=C1 RJZSSMHOEKAAPX-UHFFFAOYSA-N 0.000 description 6
• LZADXQXNWDOMDY-UHFFFAOYSA-N 2-[(3-fluorophenyl)methyl]-5-[4-(trifluoromethyl)anilino]-1,2,4-thiadiazol-3-one Chemical compound FC1=CC=CC(CN2C(N=C(NC=3C=CC(=CC=3)C(F)(F)F)S2)=O)=C1 LZADXQXNWDOMDY-UHFFFAOYSA-N 0.000 description 6
• AMUWSZXTELUHFX-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-5-[4-(trifluoromethoxy)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(S1)=NC(=O)N1CC1=CC=C(Cl)C=C1 AMUWSZXTELUHFX-UHFFFAOYSA-N 0.000 description 6
• ZNNXRHUTYUXTHC-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-5-[4-(trifluoromethyl)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(S1)=NC(=O)N1CC1=CC=C(Cl)C=C1 ZNNXRHUTYUXTHC-UHFFFAOYSA-N 0.000 description 6
• RFZWGFCULXKUMF-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methyl]-5-[4-(trifluoromethoxy)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N=C(NC=2C=CC(OC(F)(F)F)=CC=2)S1 RFZWGFCULXKUMF-UHFFFAOYSA-N 0.000 description 6
• WYBNVXBKQQMPFJ-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methyl]-5-[4-(trifluoromethyl)anilino]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N=C(NC=2C=CC(=CC=2)C(F)(F)F)S1 WYBNVXBKQQMPFJ-UHFFFAOYSA-N 0.000 description 6
• NHYKNGYFZCJBDR-UHFFFAOYSA-N 2-[2-(4-chloro-n-methylanilino)ethyl]-5-(3,4-dichloroanilino)-1,2,4-thiadiazol-3-one Chemical compound C=1C=C(Cl)C=CC=1N(C)CCN(C(N=1)=O)SC=1NC1=CC=C(Cl)C(Cl)=C1 NHYKNGYFZCJBDR-UHFFFAOYSA-N 0.000 description 6
• UQVPZZXWWFWQNN-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)sulfanylethyl]-5-(3,4-dichloroanilino)-1,2,4-thiadiazol-3-one Chemical compound C1=CC(Cl)=CC=C1SCCN1C(=O)N=C(NC=2C=C(Cl)C(Cl)=CC=2)S1 UQVPZZXWWFWQNN-UHFFFAOYSA-N 0.000 description 6
• TZSKWUDSKVQLKM-UHFFFAOYSA-N 3,4-dichloro-n-[4-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]benzamide Chemical compound C1=CC(F)=CC=C1CN(C(=O)NS1)C1=NC(=O)C1=CC=C(Cl)C(Cl)=C1 TZSKWUDSKVQLKM-UHFFFAOYSA-N 0.000 description 6
• GWQZFXMHKONFOA-UHFFFAOYSA-N 4-[(3,4-difluorophenyl)methyl]-5-[4-(trifluoromethoxy)phenyl]imino-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(F)C(F)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(OC(F)(F)F)C=C1 GWQZFXMHKONFOA-UHFFFAOYSA-N 0.000 description 6
• DEIHGKFXCGHEGK-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]-5-(3,4-dichlorophenyl)imino-1,2,4-thiadiazolidin-3-one Chemical compound C1=CC(Cl)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(Cl)C(Cl)=C1 DEIHGKFXCGHEGK-UHFFFAOYSA-N 0.000 description 6
• QGGKZABFKBNKLA-UHFFFAOYSA-N 4-[1-(4-chlorophenyl)cyclopropyl]-5-(4-chlorophenyl)imino-1,2,4-thiadiazolidin-3-one Chemical compound C1=CC(Cl)=CC=C1N=C1N(C2(CC2)C=2C=CC(Cl)=CC=2)C(=O)NS1 QGGKZABFKBNKLA-UHFFFAOYSA-N 0.000 description 6
• LVDORRLYOXNORK-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)sulfanylethyl]-5-(3,4-dichlorophenyl)imino-1,2,4-thiadiazolidin-3-one Chemical compound C1=CC(Cl)=CC=C1SCCN(C(=O)NS1)C1=NC1=CC=C(Cl)C(Cl)=C1 LVDORRLYOXNORK-UHFFFAOYSA-N 0.000 description 6
• OQCAQPYSSFQACS-UHFFFAOYSA-N 4-[[2-[(3,4-difluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]amino]benzonitrile Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)N=C(NC=2C=CC(=CC=2)C#N)S1 OQCAQPYSSFQACS-UHFFFAOYSA-N 0.000 description 6
• XKILBXRPFVVUBB-UHFFFAOYSA-N 4-[[4-[(3,4-difluorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]amino]benzonitrile Chemical compound C1=C(F)C(F)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(C#N)C=C1 XKILBXRPFVVUBB-UHFFFAOYSA-N 0.000 description 6
• HYYOUTIDAKSXEU-UHFFFAOYSA-N 4-benzhydryl-5-(3,4-dichlorophenyl)imino-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(Cl)C(Cl)=CC=C1N=C1N(C(C=2C=CC=CC=2)C=2C=CC=CC=2)C(=O)NS1 HYYOUTIDAKSXEU-UHFFFAOYSA-N 0.000 description 6
• HXIOAMUSVHJFJR-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-(2-phenoxyethyl)-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(Cl)C(Cl)=CC=C1N=C1N(CCOC=2C=CC=CC=2)C(=O)NS1 HXIOAMUSVHJFJR-UHFFFAOYSA-N 0.000 description 6
• TVKPJNODZCWEJM-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-(2-phenylethyl)-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(Cl)C(Cl)=CC=C1N=C1N(CCC=2C=CC=CC=2)C(=O)NS1 TVKPJNODZCWEJM-UHFFFAOYSA-N 0.000 description 6
• LYSHPGVDISUMCS-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-[(3,4-difluorophenyl)methyl]-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(F)C(F)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(Cl)C(Cl)=C1 LYSHPGVDISUMCS-UHFFFAOYSA-N 0.000 description 6
• AJVQFHMIZQIECE-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-[(3-fluorophenyl)methyl]-1,2,4-thiadiazolidin-3-one Chemical compound FC1=CC=CC(CN2C(SNC2=O)=NC=2C=C(Cl)C(Cl)=CC=2)=C1 AJVQFHMIZQIECE-UHFFFAOYSA-N 0.000 description 6
• MQVDUIHSNWIVBM-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-[(4-methoxyphenyl)methyl]-1,2,4-thiadiazolidin-3-one Chemical compound C1=CC(OC)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(Cl)C(Cl)=C1 MQVDUIHSNWIVBM-UHFFFAOYSA-N 0.000 description 6
• HMDIBJPBXYGKBE-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)imino-4-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(Cl)C(Cl)=CC=C1N=C1N(CC=2C=CC(=CC=2)N2N=CN=C2)C(=O)NS1 HMDIBJPBXYGKBE-UHFFFAOYSA-N 0.000 description 6
• YHLFAOGONXFOMA-UHFFFAOYSA-N 5-(4-chloroanilino)-2-[1-(4-chlorophenyl)cyclopropyl]-1,2,4-thiadiazol-3-one Chemical compound C1=CC(Cl)=CC=C1NC1=NC(=O)N(C2(CC2)C=2C=CC(Cl)=CC=2)S1 YHLFAOGONXFOMA-UHFFFAOYSA-N 0.000 description 6
• YEGKCBNUIOQIOQ-UHFFFAOYSA-N 5-[(3,4-dichlorophenyl)methylamino]-2-[(3,4-difluorophenyl)methyl]-1,2,4-thiadiazol-3-one Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)N=C(NCC=2C=C(Cl)C(Cl)=CC=2)S1 YEGKCBNUIOQIOQ-UHFFFAOYSA-N 0.000 description 6
• SDNFEWYUYLJMFS-UHFFFAOYSA-N 5-[(4-chlorophenyl)methylimino]-4-[(3,4-difluorophenyl)methyl]-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(F)C(F)=CC=C1CN(C(=O)NS1)C1=NCC1=CC=C(Cl)C=C1 SDNFEWYUYLJMFS-UHFFFAOYSA-N 0.000 description 6
• QCCSDJVVSABTKP-UHFFFAOYSA-N 5-[(6-chloropyridin-3-yl)amino]-2-[(3,4-difluorophenyl)methyl]-1,2,4-thiadiazol-3-one Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)N=C(NC=2C=NC(Cl)=CC=2)S1 QCCSDJVVSABTKP-UHFFFAOYSA-N 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 6
• 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 6
• 108010018763 Biotin carboxylase Proteins 0.000 description 6
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
• 206010060862 Prostate cancer Diseases 0.000 description 6
• 239000012267 brine Substances 0.000 description 6
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
• 229910052794 bromium Inorganic materials 0.000 description 6
• 239000006143 cell culture medium Substances 0.000 description 6
• 125000000753 cycloalkyl group Chemical group 0.000 description 6
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 6
• 239000012091 fetal bovine serum Substances 0.000 description 6
• 238000003306 harvesting Methods 0.000 description 6
• 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• 125000006239 protecting group Chemical group 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
• 238000012546 transfer Methods 0.000 description 6
• QPEXDGNCMPBSAR-UHFFFAOYSA-N 2,4-dichloro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C(=CC(Cl)=CC=2)Cl)S1 QPEXDGNCMPBSAR-UHFFFAOYSA-N 0.000 description 5
• FUXNPGYQRLEJOH-UHFFFAOYSA-N 2,6-dichloro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C(=CC=CC=2Cl)Cl)S1 FUXNPGYQRLEJOH-UHFFFAOYSA-N 0.000 description 5
• GWIUBVYZRHTBHY-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[3-oxo-2-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-thiadiazol-5-yl]acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC(S1)=NC(=O)N1CC1=CC=CC(C(F)(F)F)=C1 GWIUBVYZRHTBHY-UHFFFAOYSA-N 0.000 description 5
• YPPMKZRGLLMSDM-UHFFFAOYSA-N 2-chloro-6-fluoro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C(=CC=CC=2F)Cl)S1 YPPMKZRGLLMSDM-UHFFFAOYSA-N 0.000 description 5
• FSHRXYMLLSKYGV-UHFFFAOYSA-N 3,4-dichloro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=C(Cl)C(Cl)=CC=2)S1 FSHRXYMLLSKYGV-UHFFFAOYSA-N 0.000 description 5
• NDEIURVSGKHEAW-UHFFFAOYSA-N 3,4-dichloro-n-[2-[1-(4-fluorophenyl)cyclopropyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1C1(N2C(N=C(NC(=O)C=3C=C(Cl)C(Cl)=CC=3)S2)=O)CC1 NDEIURVSGKHEAW-UHFFFAOYSA-N 0.000 description 5
• HWOJETIWOGVVBU-UHFFFAOYSA-N 3,4-difluoro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=C(F)C(F)=CC=2)S1 HWOJETIWOGVVBU-UHFFFAOYSA-N 0.000 description 5
• FMPOTICVEOAYQK-UHFFFAOYSA-N 3,5-difluoro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=C(F)C=C(F)C=2)S1 FMPOTICVEOAYQK-UHFFFAOYSA-N 0.000 description 5
• UMWQWADVYZQVBY-UHFFFAOYSA-N 3-[[5-(4-chloroanilino)-3-oxo-1,2,4-thiadiazol-2-yl]methyl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(CN2C(N=C(NC=3C=CC(Cl)=CC=3)S2)=O)=C1 UMWQWADVYZQVBY-UHFFFAOYSA-N 0.000 description 5
• HHEABDHDGHECTF-UHFFFAOYSA-N 4-[(3,4-difluorophenyl)methyl]-5-[4-(trifluoromethyl)phenyl]imino-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(F)C(F)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(C(F)(F)F)C=C1 HHEABDHDGHECTF-UHFFFAOYSA-N 0.000 description 5
• KVQYNKBQULGFLP-UHFFFAOYSA-N 4-chloro-n-[2-[(3,4-difluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=CC(Cl)=CC=2)S1 KVQYNKBQULGFLP-UHFFFAOYSA-N 0.000 description 5
• WEDWLYRQKUTOAX-UHFFFAOYSA-N 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=CC(Cl)=CC=2)S1 WEDWLYRQKUTOAX-UHFFFAOYSA-N 0.000 description 5
• WWKBAXKETBKLRJ-UHFFFAOYSA-N 4-chloro-n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=CC(Cl)=CC=2)S1 WWKBAXKETBKLRJ-UHFFFAOYSA-N 0.000 description 5
• DTBBLXRBTAHIMV-UHFFFAOYSA-N 4-chloro-n-[2-[2-(4-chloro-n-methylanilino)ethyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1N(C)CCN(C(N=1)=O)SC=1NC(=O)C1=CC=C(Cl)C=C1 DTBBLXRBTAHIMV-UHFFFAOYSA-N 0.000 description 5
• ZUHLQVQSIGNCJR-UHFFFAOYSA-N 4-chloro-n-[2-[2-(4-chlorophenyl)sulfanylethyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1SCCN1C(=O)N=C(NC(=O)C=2C=CC(Cl)=CC=2)S1 ZUHLQVQSIGNCJR-UHFFFAOYSA-N 0.000 description 5
• JUJLKGDZODTHLE-UHFFFAOYSA-N 4-chloro-n-[3-oxo-2-(2-phenoxyethyl)-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC(S1)=NC(=O)N1CCOC1=CC=CC=C1 JUJLKGDZODTHLE-UHFFFAOYSA-N 0.000 description 5
• VFZXNINYXOCKCV-UHFFFAOYSA-N 4-chloro-n-[3-oxo-4-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-thiadiazolidin-5-ylidene]benzamide Chemical compound FC(F)(F)C1=CC=CC(CN2C(SNC2=O)=NC(=O)C=2C=CC(Cl)=CC=2)=C1 VFZXNINYXOCKCV-UHFFFAOYSA-N 0.000 description 5
• BYJQGCOTNVMBEJ-UHFFFAOYSA-N 4-chloro-n-[4-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]benzamide Chemical compound C1=CC(F)=CC=C1CN(C(=O)NS1)C1=NC(=O)C1=CC=C(Cl)C=C1 BYJQGCOTNVMBEJ-UHFFFAOYSA-N 0.000 description 5
• IHAHDANKRDSQDI-UHFFFAOYSA-N 4-fluoro-n-[3-oxo-2-[[3-(trifluoromethyl)phenyl]methyl]-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC(S1)=NC(=O)N1CC1=CC=CC(C(F)(F)F)=C1 IHAHDANKRDSQDI-UHFFFAOYSA-N 0.000 description 5
• BUZAJRPLUGXRAB-UHFFFAOYSA-N AM-251 Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(I)C=C1 BUZAJRPLUGXRAB-UHFFFAOYSA-N 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
• ONFKIPLQQJNDCW-UHFFFAOYSA-O O=C1N=C(NC(C=C2)=CC(Cl)=C2Cl)[S+](CCC2=CC=CC=C2)N1 Chemical compound O=C1N=C(NC(C=C2)=CC(Cl)=C2Cl)[S+](CCC2=CC=CC=C2)N1 ONFKIPLQQJNDCW-UHFFFAOYSA-O 0.000 description 5
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
• 230000004071 biological effect Effects 0.000 description 5
• 230000004663 cell proliferation Effects 0.000 description 5
• 239000006285 cell suspension Substances 0.000 description 5
• 235000021588 free fatty acids Nutrition 0.000 description 5
• 239000008103 glucose Substances 0.000 description 5
• 238000011534 incubation Methods 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• IOOMXAQUNPWDLL-UHFFFAOYSA-M lissamine rhodamine anion Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-M 0.000 description 5
• WSJCPQGBELBKIE-UHFFFAOYSA-N n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]-3,5-bis(trifluoromethyl)benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)S1 WSJCPQGBELBKIE-UHFFFAOYSA-N 0.000 description 5
• AGHYVPGSDQFGIP-UHFFFAOYSA-N n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]-4-(trifluoromethoxy)benzamide Chemical compound C1=CC(F)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=CC(OC(F)(F)F)=CC=2)S1 AGHYVPGSDQFGIP-UHFFFAOYSA-N 0.000 description 5
• JWCZVGWBEPZJLO-UHFFFAOYSA-N n-[2-[(4-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC(S1)=NC(=O)N1CC1=CC=C(F)C=C1 JWCZVGWBEPZJLO-UHFFFAOYSA-N 0.000 description 5
• 239000012074 organic phase Substances 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• 229940086542 triethylamine Drugs 0.000 description 5
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 4
• MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 4
• LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 4
• OGVWWGVZVJUPHF-UHFFFAOYSA-N 1,2,4-thiadiazol-3-one Chemical class O=C1N=CSN1 OGVWWGVZVJUPHF-UHFFFAOYSA-N 0.000 description 4
• DYDVLDVRIPKMEL-UHFFFAOYSA-N 4-chloro-n-[4-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]benzamide Chemical compound C1=CC(Cl)=CC=C1CN(C(=O)NS1)C1=NC(=O)C1=CC=C(Cl)C=C1 DYDVLDVRIPKMEL-UHFFFAOYSA-N 0.000 description 4
• MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 4
• CTESJDQKVOEUOY-UHFFFAOYSA-N 4-hydroxy-3-[4-(2-hydroxyphenyl)phenyl]-6-oxo-7H-thieno[2,3-b]pyridine-5-carbonitrile Chemical compound OC1=CC=CC=C1C1=CC=C(C=2C=3C(O)=C(C#N)C(=O)NC=3SC=2)C=C1 CTESJDQKVOEUOY-UHFFFAOYSA-N 0.000 description 4
• DUARHOWRVABIDW-UHFFFAOYSA-N 5-(6-chloropyridin-3-yl)imino-4-[(3,4-difluorophenyl)methyl]-1,2,4-thiadiazolidin-3-one Chemical compound C1=C(F)C(F)=CC=C1CN(C(=O)NS1)C1=NC1=CC=C(Cl)N=C1 DUARHOWRVABIDW-UHFFFAOYSA-N 0.000 description 4
• ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 4
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
• 208000024827 Alzheimer disease Diseases 0.000 description 4
• 241001644893 Entandrophragma utile Species 0.000 description 4
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
• 238000005481 NMR spectroscopy Methods 0.000 description 4
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
• ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 4
• 201000001880 Sexual dysfunction Diseases 0.000 description 4
• 239000007983 Tris buffer Substances 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 229960001456 adenosine triphosphate Drugs 0.000 description 4
• 230000001668 ameliorated effect Effects 0.000 description 4
• PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 4
• 125000002619 bicyclic group Chemical group 0.000 description 4
• 210000000481 breast Anatomy 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 239000012592 cell culture supplement Substances 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 238000003818 flash chromatography Methods 0.000 description 4
• 229940022353 herceptin Drugs 0.000 description 4
• 125000000623 heterocyclic group Chemical group 0.000 description 4
• 239000001257 hydrogen Substances 0.000 description 4
• 238000010348 incorporation Methods 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
• KIDIYOSDZIEFKU-UHFFFAOYSA-N n-[4-[(3,4-dichlorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]-3,4-difluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1C(=O)N=C1N(CC=2C=C(Cl)C(Cl)=CC=2)C(=O)NS1 KIDIYOSDZIEFKU-UHFFFAOYSA-N 0.000 description 4
• NFCQSPSNHQPUEW-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]-3,5-bis(trifluoromethyl)benzamide Chemical compound FC1=CC=CC(CN2C(SNC2=O)=NC(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=C1 NFCQSPSNHQPUEW-UHFFFAOYSA-N 0.000 description 4
• ZIPZCMQFNYAKGX-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methyl]-3-oxo-1,2,4-thiadiazolidin-5-ylidene]-4-(trifluoromethyl)benzamide Chemical compound FC1=CC=CC(CN2C(SNC2=O)=NC(=O)C=2C=CC(=CC=2)C(F)(F)F)=C1 ZIPZCMQFNYAKGX-UHFFFAOYSA-N 0.000 description 4
• MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 231100000872 sexual dysfunction Toxicity 0.000 description 4
• 239000000377 silicon dioxide Substances 0.000 description 4
• 229960001603 tamoxifen Drugs 0.000 description 4
• RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 4
• 229960000575 trastuzumab Drugs 0.000 description 4
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
• 238000001262 western blot Methods 0.000 description 4
• MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 3
• MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 3
• WNMWDOLXVKYYRA-UHFFFAOYSA-N 1-[(3,4-dichlorophenyl)carbamothioyl]-1-(2-phenoxyethyl)urea Chemical compound C=1C=C(Cl)C(Cl)=CC=1NC(=S)N(C(=O)N)CCOC1=CC=CC=C1 WNMWDOLXVKYYRA-UHFFFAOYSA-N 0.000 description 3
• HICMJPZCOSQMQQ-UHFFFAOYSA-N 1-[(3,4-dichlorophenyl)carbamothioyl]-1-[[3-(trifluoromethyl)phenyl]methyl]urea Chemical compound C=1C=C(Cl)C(Cl)=CC=1NC(=S)N(C(=O)N)CC1=CC=CC(C(F)(F)F)=C1 HICMJPZCOSQMQQ-UHFFFAOYSA-N 0.000 description 3
• MLKMNEMDFNGPBH-UHFFFAOYSA-N 2-phenoxyethylurea Chemical compound NC(=O)NCCOC1=CC=CC=C1 MLKMNEMDFNGPBH-UHFFFAOYSA-N 0.000 description 3
• JMVQCAHWDQSXTG-UHFFFAOYSA-N 4-chloro-n-(3-oxo-1,2,4-thiadiazol-5-yl)benzamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1=NC(=O)NS1 JMVQCAHWDQSXTG-UHFFFAOYSA-N 0.000 description 3
• NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 3
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
• 102000004877 Insulin Human genes 0.000 description 3
• 108090001061 Insulin Proteins 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 208000001132 Osteoporosis Diseases 0.000 description 3
• 125000002947 alkylene group Chemical group 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 229940098773 bovine serum albumin Drugs 0.000 description 3
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 230000005754 cellular signaling Effects 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 229940125396 insulin Drugs 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• KTMXIHGSQREGOP-UHFFFAOYSA-N n-[[3-(trifluoromethyl)phenyl]methylcarbamoylcarbamothioyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(CNC(=O)NC(=S)NC(=O)C=2C=CC=CC=2)=C1 KTMXIHGSQREGOP-UHFFFAOYSA-N 0.000 description 3
• 230000004770 neurodegeneration Effects 0.000 description 3
• 208000015122 neurodegenerative disease Diseases 0.000 description 3
• 229930191479 oligomycin Natural products 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 238000007747 plating Methods 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 238000001243 protein synthesis Methods 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
• 239000011541 reaction mixture Substances 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 238000010992 reflux Methods 0.000 description 3
• ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 3
• 229910000104 sodium hydride Inorganic materials 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 230000014616 translation Effects 0.000 description 3
• UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
• OSBIEFWIIINTNJ-UHFFFAOYSA-N 1,2-dichloro-4-isothiocyanatobenzene Chemical compound ClC1=CC=C(N=C=S)C=C1Cl OSBIEFWIIINTNJ-UHFFFAOYSA-N 0.000 description 2
• GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
• JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 2
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• UWEZMQMMPORRMH-UHFFFAOYSA-N 22-ethyl-7,11,14,15,28-pentahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,3',9,13-tetrone Polymers CC1(O)C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21OC(CC(C)O)C(C)CC2=O UWEZMQMMPORRMH-UHFFFAOYSA-N 0.000 description 2
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
• OIWVJMCAPAUNSB-UHFFFAOYSA-N 4-[2-(4-chloro-n-methylanilino)ethyl]-5-(3,4-dichlorophenyl)imino-1,2,4-thiadiazolidin-3-one Chemical compound C=1C=C(Cl)C=CC=1N(C)CCN1C(=O)NSC1=NC1=CC=C(Cl)C(Cl)=C1 OIWVJMCAPAUNSB-UHFFFAOYSA-N 0.000 description 2
• PAUSNTTWLQLOJH-UHFFFAOYSA-N 4-benzyl-5-(2,4,6-trinitrophenyl)imino-1,2,4-thiadiazolidin-3-one Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=C1N(CC=2C=CC=CC=2)C(=O)NS1 PAUSNTTWLQLOJH-UHFFFAOYSA-N 0.000 description 2
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
• MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 description 2
• DVNYTAVYBRSTGK-UHFFFAOYSA-N 5-aminoimidazole-4-carboxamide Chemical compound NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 description 2
• 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 2
• 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 2
• NOTGFIUVDGNKRI-UUOKFMHZSA-N AICA ribonucleotide Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 NOTGFIUVDGNKRI-UUOKFMHZSA-N 0.000 description 2
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 102100032187 Androgen receptor Human genes 0.000 description 2
• 102000014654 Aromatase Human genes 0.000 description 2
• 108010078554 Aromatase Proteins 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 101710088791 Elongation factor 2 Proteins 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• 102100026148 Free fatty acid receptor 1 Human genes 0.000 description 2
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
• DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
• 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 2
• 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 101000775732 Homo sapiens Androgen receptor Proteins 0.000 description 2
• 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 description 2
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 2
• 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
• 208000001145 Metabolic Syndrome Diseases 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
• 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 2
• 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 229940126033 PPAR agonist Drugs 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 229920001304 Solutol HS 15 Polymers 0.000 description 2
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
• 239000013504 Triton X-100 Substances 0.000 description 2
• 229920004890 Triton X-100 Polymers 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
• YIKZWHBLEGFJAG-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]methylurea Chemical compound NC(=O)NCC1=CC=CC(C(F)(F)F)=C1 YIKZWHBLEGFJAG-UHFFFAOYSA-N 0.000 description 2
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
• 230000001464 adherent effect Effects 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
• CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 230000009702 cancer cell proliferation Effects 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 201000002758 colorectal adenoma Diseases 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 230000000875 corresponding effect Effects 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 239000013058 crude material Substances 0.000 description 2
• PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 230000030609 dephosphorylation Effects 0.000 description 2
• 238000006209 dephosphorylation reaction Methods 0.000 description 2
• 238000010511 deprotection reaction Methods 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 230000002526 effect on cardiovascular system Effects 0.000 description 2
• 208000028653 esophageal adenocarcinoma Diseases 0.000 description 2
• 201000007550 esophagus adenocarcinoma Diseases 0.000 description 2
• 239000000262 estrogen Substances 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 125000005313 fatty acid group Chemical group 0.000 description 2
• 238000001640 fractional crystallisation Methods 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 201000010175 gallbladder cancer Diseases 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 210000000777 hematopoietic system Anatomy 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 235000003642 hunger Nutrition 0.000 description 2
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 229960002411 imatinib Drugs 0.000 description 2
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
• 125000002883 imidazolyl group Chemical group 0.000 description 2
• 238000003119 immunoblot Methods 0.000 description 2
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
• 125000001041 indolyl group Chemical group 0.000 description 2
• 230000002452 interceptive effect Effects 0.000 description 2
• 239000007928 intraperitoneal injection Substances 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 125000000842 isoxazolyl group Chemical group 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
• 201000007270 liver cancer Diseases 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
• 229960003105 metformin Drugs 0.000 description 2
• 230000002297 mitogenic effect Effects 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• LVWVMRBMGDJZLM-BONFEJLISA-N oligomycin D Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H](C2)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 LVWVMRBMGDJZLM-BONFEJLISA-N 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 125000001715 oxadiazolyl group Chemical group 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 239000003444 phase transfer catalyst Substances 0.000 description 2
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
• 125000003373 pyrazinyl group Chemical group 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• 125000000168 pyrrolyl group Chemical group 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 208000011581 secondary neoplasm Diseases 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 239000012679 serum free medium Substances 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• IASPBORHOMBZMY-UHFFFAOYSA-N srt1720 Chemical compound C=1N=C2C=CC=CC2=NC=1C(=O)NC1=CC=CC=C1C(N=C1SC=2)=CN1C=2CN1CCNCC1 IASPBORHOMBZMY-UHFFFAOYSA-N 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 230000037351 starvation Effects 0.000 description 2
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
• 229960001796 sunitinib Drugs 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 2
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
• 125000003831 tetrazolyl group Chemical group 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 125000001425 triazolyl group Chemical group 0.000 description 2
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
• MNULEGDCPYONBU-UIXCWHRQSA-N (1R,4E,5'S,6S,6'S,7R,8S,10R,11R,12S,14R,15S,16R,18Z,20Z,22R,25S,27R,28S,29R)-22-ethyl-7,11,14,15-tetrahydroxy-6'-[(2R)-2-hydroxypropyl]-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC[C@@H]1CC[C@@H]2O[C@]3(CC[C@H](C)[C@H](C[C@@H](C)O)O3)[C@@H](C)[C@H](OC(=O)\C=C\[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@](C)(O)[C@@H](O)[C@H](C)C\C=C/C=C\1)[C@@H]2C MNULEGDCPYONBU-UIXCWHRQSA-N 0.000 description 1
• CMMLZMMKTYEOKV-LMBDXJSXSA-N (1R,4S,5'R,6'R,10S,11R,12R,14R,15R,16S,18R,19S,20R,25S,26R,27S,29S)-4-ethyl-11,15,19-trihydroxy-6'-[(2S)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@@H]1CC[C@@H](C=CC=CC[C@H](C)[C@@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C=CC(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 CMMLZMMKTYEOKV-LMBDXJSXSA-N 0.000 description 1
• MNULEGDCPYONBU-CBLVMMTCSA-N (1R,4Z,5'S,6S,6'S,7R,8S,10R,11R,12S,14R,15S,16R,18Z,20Z,22R,25S,27R,28S,29R)-22-ethyl-7,11,14,15-tetrahydroxy-6'-[(2R)-2-hydroxypropyl]-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC[C@@H]1CC[C@@H]2O[C@]3(CC[C@H](C)[C@H](C[C@@H](C)O)O3)[C@@H](C)[C@H](OC(=O)\C=C/[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@](C)(O)[C@@H](O)[C@H](C)C\C=C/C=C\1)[C@@H]2C MNULEGDCPYONBU-CBLVMMTCSA-N 0.000 description 1
• MNULEGDCPYONBU-WABYXMGOSA-N (1S,4E,5'R,6R,6'R,7S,8R,10S,11S,12R,14S,15R,16S,18E,22S,25R,27S,28R,29S)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC[C@H]1CC[C@H]2O[C@@]3(CC[C@@H](C)[C@@H](CC(C)O)O3)[C@H](C)[C@@H](OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C1)[C@H]2C MNULEGDCPYONBU-WABYXMGOSA-N 0.000 description 1
• NLTVXGAGXODEBS-ULZPCFQASA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12r,14r,15r,16s,18r,19s,20r,21e,25r,27s,29s)-4-ethyl-11,15,19-trihydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,29-octamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Chemical compound O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H](C2)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 NLTVXGAGXODEBS-ULZPCFQASA-N 0.000 description 1
• CMMLZMMKTYEOKV-HQCSJJBPSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12r,14r,15r,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,15,19-trihydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 CMMLZMMKTYEOKV-HQCSJJBPSA-N 0.000 description 1
• QPRQJOHKNJIMGN-CPQVXFHYSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-3',13,17,23-tetron Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@@]12O[C@H](CC(C)O)[C@H](C)CC1=O QPRQJOHKNJIMGN-CPQVXFHYSA-N 0.000 description 1
• MNULEGDCPYONBU-QECWTJOCSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-QECWTJOCSA-N 0.000 description 1
• MNULEGDCPYONBU-BOXGPLBDSA-N (1r,4s,5e,5'r,6'r,7e,10s,11s,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-BOXGPLBDSA-N 0.000 description 1
• UWEZMQMMPORRMH-BOCHHXLBSA-N (1s,4r,5e,5's,6's,7e,10r,11s,12r,14s,15r,16r,18s,19r,20s,21e,25r,26r,27s,29r)-4-ethyl-11,12,15,19,26-pentahydroxy-6'-[(2r)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-3',13,17,2 Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@]2(O)C)[C@@H]1C)CC)[C@]12O[C@@H](C[C@@H](C)O)[C@@H](C)CC1=O UWEZMQMMPORRMH-BOCHHXLBSA-N 0.000 description 1
• BBXPKWAURBGKEO-MGINZONZSA-N (1s,4r,5e,5's,6's,7e,10r,11s,12r,14s,15r,16r,18s,19r,20s,21e,25r,26s,27r,29r)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2r)-2-hydroxybutyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trion Polymers C1C[C@H](C)[C@H](C[C@H](O)CC)O[C@@]21[C@@H](C)[C@@H]([C@@H]1C)OC(=O)/C=C/[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@](C)(O)[C@@H](O)[C@H](C)C/C=C/C=C/[C@H](CC)CC[C@@H]1O2 BBXPKWAURBGKEO-MGINZONZSA-N 0.000 description 1
• VVNFPMGPKYNROA-MZRZIRKFSA-N (1s,4r,5z,5's,6's,7z,10r,11s,12r,14s,15r,16r,18s,19r,20s,21e,25r,26s,27s)-4,26-diethyl-11,12,15,19-tetrahydroxy-6'-[(2r)-2-hydroxypropyl]-5',10,12,14,16,18,20,29-octamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-3',13,17,23-tet Chemical compound O([C@H]1CC[C@@H](CC)/C=C\C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@H](C1C)[C@@H]1CC)[C@@]11O[C@@H](C[C@@H](C)O)[C@@H](C)CC1=O VVNFPMGPKYNROA-MZRZIRKFSA-N 0.000 description 1
• CMMLZMMKTYEOKV-OWCJZXDLSA-N (27s)-4-ethyl-11,15,19-trihydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)C(O)C(C)CC=CC=CC(CC)CCC2O[C@]21CCC(C)C(CC(C)O)O2 CMMLZMMKTYEOKV-OWCJZXDLSA-N 0.000 description 1
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
• MNULEGDCPYONBU-YOKYSHDFSA-N (5'R,10S,11R,12S,14S,15R,16R,18R,19S,20R,26R,29S)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2S)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C=CC(=O)OC([C@H]1C)[C@H]2C)C=CC=CC(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-YOKYSHDFSA-N 0.000 description 1
• APJPYXAUMOLFTM-YLWQDIMZSA-N (5z,7z,21e)-4,26-diethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,29-octamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Chemical compound CCC1C(C2C)OC(=O)\C=C\C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC11CCC(C)C(CC(C)O)O1 APJPYXAUMOLFTM-YLWQDIMZSA-N 0.000 description 1
• 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
• 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• BIWIIIDSEMKJLP-UHFFFAOYSA-N 1,2,4-thiadiazolidin-3-one Chemical class O=C1NCSN1 BIWIIIDSEMKJLP-UHFFFAOYSA-N 0.000 description 1
• 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
• 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
• NOLHRFLIXVQPSZ-UHFFFAOYSA-N 1,3-thiazolidin-4-one Chemical compound O=C1CSCN1 NOLHRFLIXVQPSZ-UHFFFAOYSA-N 0.000 description 1
• YVLQGCNIOZPPMW-UHFFFAOYSA-N 1,4,2-dithiazole 1,1-dioxide Chemical class O=S1(=O)CSC=N1 YVLQGCNIOZPPMW-UHFFFAOYSA-N 0.000 description 1
• UXHCYSLUHBOEGI-UHFFFAOYSA-N 1-(4-bromophenyl)imino-5,6,7,8-tetrahydro-[1,3,4]thiadiazolo[3,4-a]pyridazin-3-one Chemical compound C1=CC(Br)=CC=C1N=C1N2CCCCN2C(=O)S1 UXHCYSLUHBOEGI-UHFFFAOYSA-N 0.000 description 1
• NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
• JTAADRCTUHJDFL-UHFFFAOYSA-N 2-isothiocyanato-1,3,5-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(N=C=S)C([N+]([O-])=O)=C1 JTAADRCTUHJDFL-UHFFFAOYSA-N 0.000 description 1
• IMLAIXAZMVDRGA-UHFFFAOYSA-N 2-phenoxyethanamine Chemical compound NCCOC1=CC=CC=C1 IMLAIXAZMVDRGA-UHFFFAOYSA-N 0.000 description 1
• AZYTZQYCOBXDGY-UHFFFAOYSA-N 2-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=CC=N1 AZYTZQYCOBXDGY-UHFFFAOYSA-N 0.000 description 1
• OTZBZZNWOAIAEN-UHFFFAOYSA-N 4-chlorobenzoyl isothiocyanate Chemical compound ClC1=CC=C(C(=O)N=C=S)C=C1 OTZBZZNWOAIAEN-UHFFFAOYSA-N 0.000 description 1
• 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 1
• 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
• FSXVPXKQFWSXOM-UHFFFAOYSA-N 5-(3,4-dichloroanilino)-2-(2-phenylethyl)-1,2,4-thiadiazol-3-one Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(S1)=NC(=O)N1CCC1=CC=CC=C1 FSXVPXKQFWSXOM-UHFFFAOYSA-N 0.000 description 1
• MODAULMVTKWLKJ-UHFFFAOYSA-N 5-amino-1,2,4-thiadiazol-3-one Chemical compound NC1=NC(=O)NS1 MODAULMVTKWLKJ-UHFFFAOYSA-N 0.000 description 1
• ZGZRUJMHVSASJG-UHFFFAOYSA-N 5-amino-2-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-3-one Chemical compound S1C(N)=NC(=O)N1CC1=CC=C(F)C=C1 ZGZRUJMHVSASJG-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
• 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
• MNULEGDCPYONBU-MQLHLVDXSA-N CC[C@@H]1CC[C@@H]2O[C@]3(CC[C@H](C)[C@H](C[C@@H](C)O)O3)[C@@H](C)[C@H](OC(=O)\C=C\[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@](C)(O)[C@@H](O)[C@H](C)C\C=C\C=C\1)C2C Polymers CC[C@@H]1CC[C@@H]2O[C@]3(CC[C@H](C)[C@H](C[C@@H](C)O)O3)[C@@H](C)[C@H](OC(=O)\C=C\[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@](C)(O)[C@@H](O)[C@H](C)C\C=C\C=C\1)C2C MNULEGDCPYONBU-MQLHLVDXSA-N 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 101000611262 Caenorhabditis elegans Probable protein phosphatase 2C T23F11.1 Proteins 0.000 description 1
• 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 239000005461 Canertinib Substances 0.000 description 1
• 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 102000003952 Caspase 3 Human genes 0.000 description 1
• 108090000397 Caspase 3 Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
• 208000032928 Dyslipidaemia Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 208000010228 Erectile Dysfunction Diseases 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 208000004930 Fatty Liver Diseases 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 208000002705 Glucose Intolerance Diseases 0.000 description 1
• 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 206010019708 Hepatic steatosis Diseases 0.000 description 1
• 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
• 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
• 206010022998 Irritability Diseases 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
• 101000688229 Leishmania chagasi Protein phosphatase 2C Proteins 0.000 description 1
• 208000017170 Lipid metabolism disease Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 238000007126 N-alkylation reaction Methods 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 description 1
• 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• QPRQJOHKNJIMGN-UHFFFAOYSA-N Oligomycin B Natural products CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21OC(CC(C)O)C(C)CC2=O QPRQJOHKNJIMGN-UHFFFAOYSA-N 0.000 description 1
• CMMLZMMKTYEOKV-UHFFFAOYSA-N Oligomycin C Natural products CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 CMMLZMMKTYEOKV-UHFFFAOYSA-N 0.000 description 1
• LVWVMRBMGDJZLM-UHFFFAOYSA-N Oligomycin D Natural products C1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 LVWVMRBMGDJZLM-UHFFFAOYSA-N 0.000 description 1
• BBXPKWAURBGKEO-UHFFFAOYSA-N Oligomycin F Natural products C1CC(C)C(CC(O)CC)OC21C(C)C(C1C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC1O2 BBXPKWAURBGKEO-UHFFFAOYSA-N 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 229940127315 Potassium Channel Openers Drugs 0.000 description 1
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
• 102000002067 Protein Subunits Human genes 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
• 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
• QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• NLTVXGAGXODEBS-UHFFFAOYSA-N Rutamycin B Natural products C1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 NLTVXGAGXODEBS-UHFFFAOYSA-N 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 206010039580 Scar Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
• 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
• 102000034755 Sex Hormone-Binding Globulin Human genes 0.000 description 1
• 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• 229940123464 Thiazolidinedione Drugs 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 150000001263 acyl chlorides Chemical class 0.000 description 1
• 150000001266 acyl halides Chemical class 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 125000003342 alkenyl group Chemical group 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 229960002932 anastrozole Drugs 0.000 description 1
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 229940127003 anti-diabetic drug Drugs 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 239000003472 antidiabetic agent Substances 0.000 description 1
• 239000012122 aqueous mounting media Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 229960005370 atorvastatin Drugs 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 150000004283 biguanides Chemical class 0.000 description 1
• 210000000013 bile duct Anatomy 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 229960004111 buformin Drugs 0.000 description 1
• XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 229950002826 canertinib Drugs 0.000 description 1
• OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 1
• 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 150000001733 carboxylic acid esters Chemical class 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 239000012069 chiral reagent Substances 0.000 description 1
• 125000000068 chlorophenyl group Chemical group 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 239000012568 clinical material Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 239000002178 crystalline material Substances 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 125000004188 dichlorophenyl group Chemical group 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000003255 drug test Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
• 230000019439 energy homeostasis Effects 0.000 description 1
• 230000029578 entry into host Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
• 238000006266 etherification reaction Methods 0.000 description 1
• OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• 230000004136 fatty acid synthesis Effects 0.000 description 1
• 208000010706 fatty liver disease Diseases 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 229960003765 fluvastatin Drugs 0.000 description 1
• 239000012909 foetal bovine serum Substances 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 230000007946 glucose deprivation Effects 0.000 description 1
• 230000010030 glucose lowering effect Effects 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 230000034659 glycolysis Effects 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229940116978 human epidermal growth factor Drugs 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 201000010759 hypertrophy of breast Diseases 0.000 description 1
• 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000011221 initial treatment Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
• 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
• 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 229960004891 lapatinib Drugs 0.000 description 1
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• 231100001231 less toxic Toxicity 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 229960003881 letrozole Drugs 0.000 description 1
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 230000004132 lipogenesis Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
• JCIVHYBIFRUGKO-UHFFFAOYSA-N lithium;2,2,6,6-tetramethylpiperidine Chemical compound [Li].CC1(C)CCCC(C)(C)N1 JCIVHYBIFRUGKO-UHFFFAOYSA-N 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 108010082117 matrigel Proteins 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• 229940073584 methylene chloride Drugs 0.000 description 1
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 230000004898 mitochondrial function Effects 0.000 description 1
• 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
• ZEOQPNRYUCROGZ-UHFFFAOYSA-N n,n-dibutylbutan-1-amine;hydrobromide Chemical compound [Br-].CCCC[NH+](CCCC)CCCC ZEOQPNRYUCROGZ-UHFFFAOYSA-N 0.000 description 1
• PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 210000001989 nasopharynx Anatomy 0.000 description 1
• 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
• 238000009099 neoadjuvant therapy Methods 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 125000006574 non-aromatic ring group Chemical group 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• 210000004287 null lymphocyte Anatomy 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• QPRQJOHKNJIMGN-WVUAJZTGSA-N oligomycin B Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@]12O[C@@H](C[C@@H](C)O)[C@@H](C)CC1=O QPRQJOHKNJIMGN-WVUAJZTGSA-N 0.000 description 1
• CMMLZMMKTYEOKV-RDKHTNMBSA-N oligomycin C Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 CMMLZMMKTYEOKV-RDKHTNMBSA-N 0.000 description 1
• QPRQJOHKNJIMGN-UXAQBZNTSA-N oligomycin b Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@@]12O[C@H](C[C@H](C)O)[C@H](C)CC1=O QPRQJOHKNJIMGN-UXAQBZNTSA-N 0.000 description 1
• CMMLZMMKTYEOKV-JEKNLLRFSA-N oligomycin c Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 CMMLZMMKTYEOKV-JEKNLLRFSA-N 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
• 229960003243 phenformin Drugs 0.000 description 1
• ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
• 238000002428 photodynamic therapy Methods 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 229960005095 pioglitazone Drugs 0.000 description 1
• 229960005235 piperonyl butoxide Drugs 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
• 229920000155 polyglutamine Polymers 0.000 description 1
• 108010040003 polyglutamine Proteins 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
• ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
• 229940116357 potassium thiocyanate Drugs 0.000 description 1
• RFAKLMBNSZNUNX-UHFFFAOYSA-N potassium;isothiocyanate Chemical compound [K+].[N-]=C=S RFAKLMBNSZNUNX-UHFFFAOYSA-N 0.000 description 1
• 235000008476 powdered milk Nutrition 0.000 description 1
• 229960002965 pravastatin Drugs 0.000 description 1
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 239000013557 residual solvent Substances 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 229940016667 resveratrol Drugs 0.000 description 1
• 235000021283 resveratrol Nutrition 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• 229960000672 rosuvastatin Drugs 0.000 description 1
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
• LVWVMRBMGDJZLM-WXPRFNGZSA-N rutamycin Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H](C2)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 LVWVMRBMGDJZLM-WXPRFNGZSA-N 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 101150026756 sir1 gene Proteins 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 230000016160 smooth muscle contraction Effects 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
• 231100000240 steatosis hepatitis Toxicity 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 239000012089 stop solution Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000003107 substituted aryl group Chemical group 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 231100000338 sulforhodamine B assay Toxicity 0.000 description 1
• 238000003210 sulforhodamine B staining Methods 0.000 description 1
• 235000011149 sulphuric acid Nutrition 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000008399 tap water Substances 0.000 description 1
• 235000020679 tap water Nutrition 0.000 description 1
• 238000003419 tautomerization reaction Methods 0.000 description 1
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• 239000012085 test solution Substances 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 150000001467 thiazolidinediones Chemical class 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 230000009772 tissue formation Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
• 239000013638 trimer Substances 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
• 229960001641 troglitazone Drugs 0.000 description 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
• 229960000241 vandetanib Drugs 0.000 description 1
• 229950000578 vatalanib Drugs 0.000 description 1
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1
• 150000003738 xylenes Chemical class 0.000 description 1